EXAS Exact Sciences Corporation

Price (delayed)

$120.96

Market cap

$18.2B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$2.13

Enterprise value

$19.1B

Sector: Healthcare
Industry: Diagnostics & Research
EXACT Sciences Corp. is a molecular diagnostics company, which focuses on the early detection and prevention of colorectal cancer. It developed Cologuard, a screening test for the early detection of colorectal cancer and pre-cancer. The company was founded on February 10, 1995 and is headquartered in Madison, WI.

Highlights

EXAS's gross profit has surged by 84% year-on-year and by 17% since the previous quarter
EXAS's revenue has surged by 82% year-on-year and by 17% since the previous quarter
The company's quick ratio has surged by 127% YoY but it fell by 6% QoQ
Exact Sciences's EPS has plunged by 117% from the previous quarter and by 25% YoY
The company's net income has shrunk by 116% QoQ and by 55% YoY

Key stats

What are the main financial stats of EXAS
Market
Shares outstanding
150.42M
Market cap
$18.2B
Enterprise value
$19.1B
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
7.77
Price to sales (P/S)
13.75
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
14.46
Earnings
Revenue
$1.32B
EBIT
-$440.18M
EBITDA
-$276.78M
Free cash flow
-$91.69M
Per share
EPS
-$2.13
Free cash flow per share
-$0.61
Book value per share
$15.56
Revenue per share
$8.8
TBVPS
$14.95
Balance sheet
Total assets
$4.35B
Total liabilities
$2.02B
Debt
$1.71B
Equity
$2.34B
Working capital
$1.35B
Liquidity
Debt to equity
0.73
Current ratio
6.35
Quick ratio
5.89
Net debt/EBITDA
-3.28
Margins
EBITDA margin
-21%
Gross margin
75.5%
Net margin
-25.3%
Operating margin
-34%
Efficiency
Return on assets
-8%
Return on equity
-13.8%
Return on invested capital
-17.1%
Return on capital employed
-10.7%
Return on sales
-33.3%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

EXAS stock price

How has the Exact Sciences stock price performed over time
Intraday
2.34%
1 week
0.35%
1 month
-2.32%
1 year
49.31%
YTD
30.8%
QTD
18.65%

Financial performance

How have Exact Sciences's revenue and profit performed over time
Revenue
$1.32B
Gross profit
$996.93M
Operating income
-$448.83M
Net income
-$333.78M
Gross margin
75.5%
Net margin
-25.3%
The operating income has dropped by 140% year-on-year and by 60% since the previous quarter
The company's net income has shrunk by 116% QoQ and by 55% YoY
The company's net margin has shrunk by 85% QoQ but it rose by 15% YoY
EXAS's gross profit has surged by 84% year-on-year and by 17% since the previous quarter

Growth

What is Exact Sciences's growth rate over time

Valuation

What is Exact Sciences stock price valuation
P/E
N/A
P/B
7.77
P/S
13.75
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
14.46
Exact Sciences's EPS has plunged by 117% from the previous quarter and by 25% YoY
The stock's price to book (P/B) is 52% more than its last 4 quarters average of 5.1 but 9% less than its 5-year quarterly average of 8.5
The company's equity fell by 7% QoQ
EXAS's revenue has surged by 82% year-on-year and by 17% since the previous quarter
EXAS's price to sales (P/S) is 25% less than its 5-year quarterly average of 18.4 but 22% more than its last 4 quarters average of 11.3

Efficiency

How efficient is Exact Sciences business performance
The company's return on invested capital has shrunk by 86% YoY and by 36% QoQ
EXAS's return on assets has dropped by 82% since the previous quarter but it is up by 37% year-on-year
The ROE has plunged by 82% from the previous quarter but it has soared by 53% YoY
Exact Sciences's ROS has plunged by 53% YoY and by 42% from the previous quarter

Dividends

What is EXAS's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for EXAS.

Financial health

How did Exact Sciences financials performed over time
The total assets is 116% more than the total liabilities
The total assets has soared by 148% YoY but it has contracted by 2.5% from the previous quarter
EXAS's current ratio has soared by 131% YoY but it is down by 6% QoQ
The company's debt is 27% lower than its equity
EXAS's debt to equity is down by 33% year-on-year but it is up by 7% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.